Final Dividend of Rs. 1.50 (30%) per equity shares of Face Value of Rs. 5 each for the Financial year ended 31/03/2026
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma's Board recommended a final dividend of Rs. 1.50 per equity share (30% payout on Rs. 5 face value) for FY2025-26, subject to shareholder approval at the AGM on 12th August 2026. The record date is fixed for 5th August 2026. The company also reported audited FY2026 results with total revenue of Rs. 77,601.30 lakhs (up 15.6% YoY from Rs. 67,097.02 lakhs), but net profit after tax declined to Rs. 4,104.61 lakhs (vs Rs. 4,735.19 lakhs in FY2025). EBITDA stood at Rs. 6,607.59 lakhs with an 8.56% margin. Notably, the company had completed a 1:1 bonus share issuance in July 2025, doubling the paid-up equity capital from Rs. 2,505.60 lakhs to Rs. 5,011.20 lakhs. Additionally, several promoter group members (holding 0.95% stake) have sought reclassification to public category.
The dividend provides a 30% yield on face value but profit decline of ~13% YoY and a significant foreign exchange loss (Rs. 288.72 lakhs) in Q4 may weigh on sentiment. The bonus issue completed last year has doubled share count, diluting per-share metrics.